Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases.

We are committed to providing relevant, accurate and timely information to investors and the financial community. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH).